Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.

Eva VersteijneJ A VogelM G BesselinkO R C BuschJ W WilminkJ G DaamsC H J van EijckBas Groot KoerkampC R N RaschG van Tienhovennull null

Published in: The British journal of surgery (2018)

Neoadjuvant treatment appears to improve overall survival by intention to treat, despite lower overall resection rates for resectable or borderline resectable pancreatic cancer. PROSPERO registration number: CRD42016049374.

Keyphrases

locally advanced
rectal cancer
systematic review
liver metastases
squamous cell carcinoma
minimally invasive
randomized controlled trial
atrial fibrillation
percutaneous coronary intervention
case control
smoking cessation